NO20024639L - Malonaminsyrer og derivater derav som tyroid-reseptor ligander - Google Patents

Malonaminsyrer og derivater derav som tyroid-reseptor ligander

Info

Publication number
NO20024639L
NO20024639L NO20024639A NO20024639A NO20024639L NO 20024639 L NO20024639 L NO 20024639L NO 20024639 A NO20024639 A NO 20024639A NO 20024639 A NO20024639 A NO 20024639A NO 20024639 L NO20024639 L NO 20024639L
Authority
NO
Norway
Prior art keywords
derivatives
receptor ligands
thyroid receptor
malonamic acids
malonamic
Prior art date
Application number
NO20024639A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024639D0 (no
Inventor
Gary Erik Aspnes
Yuan-Ching Phoebe Chiang
Kimberley Gail Estep
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20024639D0 publication Critical patent/NO20024639D0/no
Publication of NO20024639L publication Critical patent/NO20024639L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20024639A 2000-03-31 2002-09-27 Malonaminsyrer og derivater derav som tyroid-reseptor ligander NO20024639L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19361800P 2000-03-31 2000-03-31
PCT/IB2001/000317 WO2001072692A1 (fr) 2000-03-31 2001-03-07 Acides malonamiques et leurs derives en tant que ligands du recepteur de thyroide

Publications (2)

Publication Number Publication Date
NO20024639D0 NO20024639D0 (no) 2002-09-27
NO20024639L true NO20024639L (no) 2002-09-27

Family

ID=22714346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024639A NO20024639L (no) 2000-03-31 2002-09-27 Malonaminsyrer og derivater derav som tyroid-reseptor ligander

Country Status (38)

Country Link
US (1) US20070173548A1 (fr)
EP (1) EP1268404B1 (fr)
JP (1) JP3866977B2 (fr)
KR (1) KR20020089420A (fr)
CN (1) CN1422246A (fr)
AP (1) AP2002002634A0 (fr)
AR (1) AR033516A1 (fr)
AT (1) ATE382602T1 (fr)
AU (1) AU2001237665A1 (fr)
BG (1) BG107036A (fr)
BR (1) BR0109625A (fr)
CA (1) CA2403902C (fr)
CR (1) CR6742A (fr)
CZ (1) CZ20023190A3 (fr)
DE (1) DE60132181D1 (fr)
DZ (1) DZ3276A1 (fr)
EA (1) EA200200921A1 (fr)
EE (1) EE200200566A (fr)
GT (1) GT200100041A (fr)
HK (1) HK1052498A1 (fr)
HU (1) HUP0300329A3 (fr)
IL (1) IL151376A0 (fr)
IS (1) IS6516A (fr)
MA (1) MA26886A1 (fr)
MX (1) MXPA02009702A (fr)
NO (1) NO20024639L (fr)
NZ (1) NZ520660A (fr)
OA (1) OA12237A (fr)
PA (1) PA8513801A1 (fr)
PE (1) PE20011186A1 (fr)
PL (1) PL358596A1 (fr)
SK (1) SK13762002A3 (fr)
SV (1) SV2002000357A (fr)
TN (1) TNSN01048A1 (fr)
TR (1) TR200202249T2 (fr)
WO (1) WO2001072692A1 (fr)
YU (1) YU74102A (fr)
ZA (1) ZA200207444B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
PL201790B1 (pl) * 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
WO2002051805A1 (fr) * 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Derives de l'indole utilises comme ligands de recepteurs de la thyroide
GB2374009A (en) * 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
KR20040027927A (ko) 2001-08-24 2004-04-01 카로 바이오 아베 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CA2546601A1 (fr) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
WO2006128058A2 (fr) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
CN102137837A (zh) * 2008-04-11 2011-07-27 株式会社医药分子设计研究所 Pai-1抑制剂
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
MX2011004347A (es) 2008-10-27 2011-05-25 Cadila Healthcare Ltd Ligandos de receptores de la tiroides.
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2010086878A2 (fr) 2009-01-09 2010-08-05 Cadila Healthcare Limited Modulateurs des récepteurs de la thyroïde
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
DK2695611T3 (en) 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
US20170112741A1 (en) * 2014-04-09 2017-04-27 Goldcrest Medicine Institute Co., Ltd. Agent for ameliorating skin symptom, hair growth agent or slimming agent
MX2019005730A (es) 2016-11-21 2019-10-21 Viking Therapeutics Inc Metodo para tratar enfermedad de almacenamiento de glucogeno.
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CN107474007B (zh) * 2017-08-28 2019-04-19 上海再启生物技术有限公司 一种制备3，6-二羟基苯二甲酰亚胺的方法
EP3768690A4 (fr) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Formes cristallines et procédés de production de formes cristallines d'un composé
WO2020117962A1 (fr) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions pour le traitement de la fibrose et de l'inflammation
CN112300133B (zh) * 2019-07-31 2024-07-30 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
EP3878837A1 (fr) * 2020-03-11 2021-09-15 OM Pharma SA Dérivés d'hydroquinone 2,5- ou 2,6-disubstitutuées avec au moins un groupe carboxy, sulfo ou amido utiles comme médicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) * 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) * 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5232947A (en) * 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DK0580550T3 (da) * 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamidsyrederivater som hypercholesterolæmiske midler
CO5160290A1 (es) * 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
CA2374263A1 (fr) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Methode de traitement de la perte des cheveux a l'aide de derives de diphenylether
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands

Also Published As

Publication number Publication date
NZ520660A (en) 2004-03-26
EA200200921A1 (ru) 2003-02-27
ATE382602T1 (de) 2008-01-15
OA12237A (en) 2003-10-23
TR200202249T2 (tr) 2003-01-21
PE20011186A1 (es) 2001-11-15
NO20024639D0 (no) 2002-09-27
DE60132181D1 (de) 2008-02-14
US20070173548A1 (en) 2007-07-26
KR20020089420A (ko) 2002-11-29
BR0109625A (pt) 2003-04-22
YU74102A (sh) 2006-03-03
CN1422246A (zh) 2003-06-04
CA2403902A1 (fr) 2001-10-04
PL358596A1 (en) 2004-08-09
AU2001237665A1 (en) 2001-10-08
EP1268404B1 (fr) 2008-01-02
HK1052498A1 (zh) 2003-09-19
CA2403902C (fr) 2007-04-24
TNSN01048A1 (fr) 2005-11-10
MA26886A1 (fr) 2004-12-20
MXPA02009702A (es) 2003-03-27
SK13762002A3 (sk) 2004-01-08
GT200100041A (es) 2002-03-22
EP1268404A1 (fr) 2003-01-02
IS6516A (is) 2002-08-21
BG107036A (bg) 2003-04-30
AR033516A1 (es) 2003-12-26
JP2003528847A (ja) 2003-09-30
JP3866977B2 (ja) 2007-01-10
CR6742A (es) 2003-11-25
PA8513801A1 (es) 2002-02-21
HUP0300329A3 (en) 2004-08-30
IL151376A0 (en) 2003-04-10
CZ20023190A3 (cs) 2003-10-15
HUP0300329A2 (hu) 2003-07-28
WO2001072692A1 (fr) 2001-10-04
AP2002002634A0 (en) 2002-09-30
SV2002000357A (es) 2002-07-16
EE200200566A (et) 2004-06-15
ZA200207444B (en) 2003-09-17
DZ3276A1 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
NO20024639D0 (no) Malonaminsyrer og derivater derav som tyroid-reseptor ligander
NO2019016I1 (no) dasatinib
NO20014217D0 (no) Oksaminsyrer og derivater som tyroid reseptor ligander
NO2007002I2 (no) Sorafenib
ATE540013T1 (de) Naphthalinderivate
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
NO20025590L (no) Fenylglycin-derivater
DE60102994D1 (de) Fritiergerät
ATE288437T1 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
NO20023367L (no) Glyburide-preparat
DE50114386D1 (de) Ng
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
DE60106821D1 (de) Fritiergerät
NO20001294D0 (no) Måler for skyvekraft
DE60105231D1 (de) Fritiergerät
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
DE60100532D1 (de) Fritiergerät
DE60100772D1 (de) Fritiergerät
FR2815239B1 (fr) Barbecue
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater
FR2805803B1 (fr) Monte-materiaux
DK1157001T3 (da) Oxamsyrer og deres derivater som thyreoidea-receptorligander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application